Source: Pharmabiz

DICE: Eli Lilly completes acquisition of DICE Therapeutics

Eli Lilly and Company announced the successful completion of its acquisition of DICE Therapeutics, Inc. The acquisition expands Lilly's immunology portfolio to include DICE's novel oral therapeutic

Read full article »

DICE's Competitors | DICE's News | DICE's Financials

Followers on Owler

Annual Revenue

$100K-5.0M

Employees

25-100

Founder & CEO

Kevin Judice

CEO Approval Rating

90/100

DICE is a California-based biopharmaceutical company that researches and develops novel oral therapeutics for the treatment of chronic autoimmune and inflammatory diseases.